Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.Amadis
    Tel: 86-571-89925085

  • Mobile:
  • Tel:86-571-89925085
  • Fax:86-571-89925065
  • URL:http://www.amadischem.com
  • Province/state:Zhejiang
  • City:Hangzhou
  • Street:Watts Cosine.No.166.Xiangmao Road.
  • MaxCard:
Home > Products >  High Quality low price 2152628-33-4Selpercatinib On Sale

High Quality low price 2152628-33-4Selpercatinib On Sale CAS NO.2152628-33-4

  • Min.Order: 10 Metric Ton
  • Payment Terms: L/C,T/T,Other
  • Product Details

Keywords

  • High Quality 2152628-33-4
  • low price 2152628-33-4
  • Selpercatinib On Sale

Quick Details

  • ProName: High Quality low price 2152628-33-4Sel...
  • CasNo: 2152628-33-4
  • Appearance: Powder or liquid
  • Application: Medicinal Chemistry Biomedicine Phar...
  • DeliveryTime: Goods in stock
  • PackAge: According to customer
  • Port: Shanghai
  • ProductionCapacity: Metric Ton/Day
  • Purity: 97%
  • Storage: Store in a tightly closed container, i...
  • Transportation: Fedex,DHL,TNT,BY SEA and BY AIR
  • LimitNum: 10 Metric Ton
  • Moisture Content: 5%
  • Grade: Industrial Grade,Reagent Grade

Superiority

Selpercatinib, also known as LOXO-292, is a potent and selective RET inhibitor with antineoplastic properties. LOXO-292 selectively binds to and targets various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. Selpercatinib was approved in May 2020.
 
LOXO-292 is an inhibitor of the receptor tyrosine kinase RET.1 It inhibits the phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM). LOXO-292 selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold. It improves survival in a CCDC6-RET gene fusion-positive orthotopic patient-derived xenograft (PDX) mouse model of brain cancer when administered at a dose of 30 mg/kg. Formulations containing LOXO-292 have been used in the treatment of RET mutation- or gene fusion-positive lung or thyroid cancers.
 

Details

Alternate Name 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile; LOXO-292
Appearance White to off-White powder
CAS # 2152628-33-4
Molecular Formula C??H??N?O?
Molecular Weight 525.6
Purity >98%
Solubility ~8 mg/ml in DMSO. Ultrasonication can be done to improve solubility.
SMILES CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
InChi InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
InChi Key XIIOFHFUYBLOLW-UHFFFAOYSA-N
PubChem CID 134436906
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions RT
USAGE For Research Use Only! Not For Use in Humans.

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog